In an effort to overcome these limitations, targeted therapies are currently an area of research focus due to our progressive understanding of tumor molecular biology and the tumor microenvironment (TME), including medications targeting the epidermal growth factor receptor, such as gefitinib (1,2) and erlotinib (1,3), and those targeting the vascular endothelial growth factor (VEGF) signaling pathways, such as bevacizumab (4). Here, VEGFA is linked to neoplasm.